Tonix Pharmaceuticals: A Long-Term Growth Story
As biotechnology stocks continue to impress, investors may want to consider a micro-cap company that has the potential for significant returns over the coming years. That stock is Tonix Pharmaceuticals (NASDAQ:TNXP).
Tonix Pharmaceuticals is developing innovative prescription medications for challenging disorders of the central nervous system. The company is targeting conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. The company’s technology platform has been shown to improve the quality of sleep in patients with chronic pain syndrome.
Over the past three months, shares of Tonix have surged by more than 350 percent as investors and institutions have begun to realize the potential that the company’s technology possesses. The company is currently evaluating TNX-102 SL for the treatment of fibromyalgia and post-traumatic stress disorder (or, PTSD). Fibromyalgia is a common syndrome in which a person has long-term, body-wide pain and tenderness in the joints, muscles, tendons, and other soft tissues. It is also linked to fatigue, sleep problems, headaches, depression, and anxiety.